Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients—authors' reply

Volkers, Adriaan; Straatmijer, Tessa; Duijvestein, Marjolijn; Löwenberg, Mark; Meulen, Andrea Van Der; D’Haens, Geert

doi:10.1111/apt.17407

Cited by 4 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Safety concerns have been raised regarding switch back to IV once being established on SC treatment. 22 , 23 In the present study, 4 patients switched back to IV due to ISRs, and 3 of these patients experienced AEs at consecutive infusions, 1 case leading to discontinuation of VDZ. Our observations are consistent with observations made by Volkers et al, where 1 out of 4 patients switching back to IV due to ISRs had to discontinue VDZ.…”

Section: Discussionmentioning

confidence: 57%

See 1 more Smart Citation

Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study

Wiken,

Høivik,

Anisdahl

et al. 2024

Crohn's &Amp; Colitis 360

View full text Add to dashboard Cite

Background Vedolizumab has since 2021 been available as a subcutaneous formulation. We aimed to assess 18-month drug persistence and possible predictive factors associated with discontinuation, safety, serum drug profile, drug dosing and disease activity in a real world cohort of patients with inflammatory bowel disease switched from intravenous to subcutaneous vedolizumab maintenance treatment. Methods Eligible patients were switched to subcutaneous vedolizumab and followed for 18 months or until discontinuation of subcutaneous treatment. Data on preferred route of administration, adverse events, drug dosing, serum-vedolizumab, disease activity, faecal calprotectin and C-reactive protein were collected. Persistence was described using Kaplan Meier analysis. Impact of clinical and biochemical variables on persistence was analysed with Cox proportional hazard models. Results We included 108 patients, and the estimated 18-month drug persistence was 73.6% (95% CI [64.2-80.1]). Patients in clinical remission at switch were less likely to discontinue SC treatment (HR=0.34, 95% CI [0.16-0.73], p=0.006), and patients favouring intravenous treatment at switch were almost three times more likely to discontinue (HR=2.78, 95% CI [1.31-5.90], p=0.008). Four patients discontinued subcutaneous vedolizumab due to injection site reactions. At 18 months, 88% of patients administered subcutaneous vedolizumab with an interval of ≥14 days, and serum-vedolizumab was 39.1 mg/L. Disease activity was stable during follow-up. Conclusion Three of four patients remained on subcutaneous vedolizumab after 18 months, a large proportion received treatment at standard dosing interval, and disease activity remained stable. This indicates that switching from intravenous to subcutaneous vedolizumab treatment is convenient and safe.

show abstract

Section: Discussionmentioning

confidence: 57%

“… 4 , 5 , 15–18 Yet, recently published reports disclosed that some patients with AEs on SC VDZ, experienced AEs also when switching back to IV treatment. 22 , 23 Thus, further safety data when switching back to IV VDZ are needed.…”

Section: Introductionmentioning

confidence: 99%

Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study

Wiken,

Høivik,

Anisdahl

et al. 2024

Crohn's &Amp; Colitis 360

View full text Add to dashboard Cite

show abstract

Recurrent skin reaction at the site of former subcutaneous injection after switching back to intravenous vedolizumab

Cañete,

Gonzalez-Gonzalez,

Domènech

2024

Gastroenterología y Hepatología (English Edition)

View full text Add to dashboard Cite

Recurrent skin reaction at the site of former subcutaneous injection after switching back to intravenous vedolizumab

Cañete

González-González

Domènech

2024

Gastroenterología y Hepatología

View full text Add to dashboard Cite

Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients—authors' reply

Abstract: LINKED CONTENT This article is linked to Volkers et al papers. To view these articles, visit https://doi.org/10.1111/apt.17153 and https://doi.org/10.1111/apt.17395

Cited by 4 publications

References 6 publications

Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study

Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study

Recurrent skin reaction at the site of former subcutaneous injection after switching back to intravenous vedolizumab

Recurrent skin reaction at the site of former subcutaneous injection after switching back to intravenous vedolizumab

Contact Info

Product

Resources

About